MedTrace Logo

Lanreotide as Treatment of Polycystic Livers

NCT00565097 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2009-02-17

No results posted yet for this study

Summary

To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.

Conditions

  • Polycystic Liver Disease
  • Hepatomegaly
  • Liver Diseases
  • Polycystic Kidney, Autosomal Dominant

Interventions

DRUG

Placebo

DRUG

Lanreotide

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Joost PH Drenth, MD, PhD · Radboud University Medical Center Nijmegen

  • Loes van Keimpema, MSc · Radboud University Medical Center Nijmegen

  • Frederik Nevens, MD, PhD · University Hospital Gasthuisberg, University of Leuven

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00565097 on ClinicalTrials.gov